• IBA Notice of Half Year 2024 Results and Conference Call

    Источник: Nasdaq GlobeNewswire / 01 авг 2024 01:00:00   America/New_York

    HY24 results webcast to take place on
    Thursday, 29 August 2024 at 3pm CEST

    Louvain-la-Neuve, Belgium, 1 August 2024 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, announces today that it will publish its consolidated results for the half year 2024 on Thursday, 29 August 2024 at 7am CEST.

    Conference Call Information

    IBA’s management team will host a conference call and webcast conducted in English to present the half year results, followed by a Q&A session.

    The conference call will be held on Thursday, 29 August 2024 at 3pm CEST / 2pm BST / 9am EDT / 6am PDT as a Teams webinar and can be accessed via this link.

    If you would like to join by phone only, please dial (Phone conference ID 533 540 829#)

    Belgium:                     +32 2 890 97 20
    UK:                             +44 20 3321 5200
    NL:                              +31 20 708 6901
    LU:                              +352 27 87 00 02
    US:                             +1 347-991-7591
    FR:                              +33 1 70 99 53 51

    The presentation will be available on IBA’s investor relations website and on:
    https://www.iba-worldwide.com/iba-half-year-2024-results-presentation-and-press-release shortly before the call.

    To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.

    For participants who do not have the Teams application installed, please follow the process described in this link to access the conference.

    ENDS

    About IBA

    IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,000 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

    IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

    More information can be found at: www.iba-worldwide.com

    CONTACTS

    Soumya Chandramouli
    Chief Financial Officer
    +32 10 475 890
    Investorrelations@iba-group.com

    Olivier Lechien
    Corporate Communication Director
    +32 10 475 890
    communication@iba-group.com

    ICR Consilium
    Amber Fennell, Matthew Neal, Lucy Featherstone
    +44 (0) 20 3709 5700
    IBA@consilium-comms.com

    Attachment


Опубликовать